Literature DB >> 14618340

Intravenous treatment of experimental Staphylococcus aureus endophthalmitis: imipenem versus the combination of ceftazidime and amikacin.

Michael Engelbert1, Herminia Miño de Kaspar, Martina Mette, Martin Thiel, Christopher N Ta, Thomas Grasbon, Markus Schulze-Schwering, Volker Klauss, Anselm Kampik.   

Abstract

BACKGROUND: To compare the efficacy of intravenous (IV) imipenem (IPM) and a combination of IV ceftazidime (CAZ) and amikacin (AN) in the treatment of Staphylococcus aureus endophthalmitis in a rabbit model.
METHODS: Right eyes of 60 albino rabbits were injected with 1000 colony-forming units of S. aureus intravitreally. After 24 h, treatment with either IV IPM (37.5 mg/kg) every 8 h ( n=18) or IV CAZ (50 mg/kg) and AN (10 mg/kg) every 8 hours ( n=18) was begun and continued until the animals were killed at the indicated timepoints; 24 control animals received no treatment. The concentration of bacteria in the vitreous from six animals per group was determined microbiologically on days 2, 3, and 5 after infection, and histologic examination was performed on all eyes.
RESULTS: The number of eyes with positive cultures on day 5 was lower in the group that received IV IPM (2/6) compared with the IV CAZ/AN group (4/6) and the control group (6/6). For the culture-positive eyes, the bacterial concentrations were significantly lower for the IV IPM group compared with the IV CAZ/AN group on days 2 and 5 ( P<0.05 and P<0.0065, respectively), but not on day 3 ( P <0.8. Bacterial counts in both treatment groups were significantly lower than in the control group ( P<0.005). Eyes in all groups, however, showed severe intraocular inflammation.
CONCLUSIONS: IV IPM is more effective than is IV CAZ/AN in reducing the number of bacteria in an animal model of S.aureus endophthalmitis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14618340     DOI: 10.1007/s00417-003-0768-8

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  28 in total

1.  Intravitreal penetration of oral ciprofloxacin in humans.

Authors:  F Z el Baba; M D Trousdale; W J Gauderman; D G Wagner; P E Liggett
Journal:  Ophthalmology       Date:  1992-04       Impact factor: 12.079

2.  Persistent endophthalmitis after intravitreal antimicrobial therapy.

Authors:  A Shaarawy; M G Grand; T A Meredith; H E Ibanez
Journal:  Ophthalmology       Date:  1995-03       Impact factor: 12.079

3.  BB-K8: A new aminoglycoside for intravitreal injection in bacterial endophthalmitis.

Authors:  P Nelsen; G A Peyman; T O Bennett
Journal:  Am J Ophthalmol       Date:  1974-07       Impact factor: 5.258

4.  The intraocular penetration of ampicillin, methicillin, and oxacillin.

Authors:  R E Records; P P Ellis
Journal:  Am J Ophthalmol       Date:  1967-07       Impact factor: 5.258

5.  Drug-induced retinal toxicity in albino rabbits: the effects of imipenem and aztreonam.

Authors:  A Loewenstein; E Zemel; M Lazar; I Perlman
Journal:  Invest Ophthalmol Vis Sci       Date:  1993-11       Impact factor: 4.799

Review 6.  Thienamycin: development of imipenen-cilastatin.

Authors:  F M Kahan; H Kropp; J G Sundelof; J Birnbaum
Journal:  J Antimicrob Chemother       Date:  1983-12       Impact factor: 5.790

7.  Pharmacokinetic profile of imipenem/cilastatin in normal volunteers.

Authors:  G L Drusano; H C Standiford
Journal:  Am J Med       Date:  1985-06-07       Impact factor: 4.965

8.  Penetration of imipenem into human aqueous and vitreous humor.

Authors:  J L Axelrod; J C Newton; R M Klein; R L Bergen; M Z Sheikh
Journal:  Am J Ophthalmol       Date:  1987-12-15       Impact factor: 5.258

9.  The influence of aphakia and vitrectomy on experimental retinal toxicity of aminoglycoside antibiotics.

Authors:  J H Talamo; D J D'Amico; L A Hanninen; K R Kenyon; E T Shanks
Journal:  Am J Ophthalmol       Date:  1985-12-15       Impact factor: 5.258

10.  Human vitreous penetration of imipenem.

Authors:  J P Adenis; M Mounier; J L Salomon; F Denis
Journal:  Eur J Ophthalmol       Date:  1994 Apr-Jun       Impact factor: 1.922

View more
  2 in total

Review 1.  Modeling intraocular bacterial infections.

Authors:  Roger A Astley; Phillip S Coburn; Salai Madhumathi Parkunan; Michelle C Callegan
Journal:  Prog Retin Eye Res       Date:  2016-05-03       Impact factor: 21.198

2.  Intravitreal vancomycin and amikacin versus intravenous imipenem in the treatment of experimental Staphylococcus aureus endophthalmitis.

Authors:  Michael Engelbert; Herminia Miño de Kaspar; Martin Thiel; Thomas Grasbon; Christopher N Ta; Markus Schulze-Schwering; Volker Klauss; Anselm Kampik
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-02-24       Impact factor: 3.117

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.